Sector News

GE Healthcare’s CEO John Dineen to step down

October 9, 2014
Life sciences
GE Healthcare is changing up its leadership Monday, with current president and CEO John Dineen stepping down, effective immediately.
 
The top role will be filled by John Flannery, who was most recently the senior vice president of business development for GE, the company said.
 
The leadership shift is the latest to take place under chairman and CEO Jeff Immelt. Over the past 15 months, Immelt replaced top leaders at GE Capital and GE Oil & Gas and named Jeff Bornstein as the new chief financial officer of GE.
 
Dineen led the $20 billion health unit for seven years and worked within GE for 28 years. He previously held senior positions in GE Industrial Systems, Plastics, Transportation and Healthcare. Dineen is leaving the company to explore “new leadership opportunities,” according to the statement.
 
“John successfully led GE Healthcare during a period of growth, portfolio diversification and market volatility,” Jeff Immelt, GE chairman and CEO, said. “Thanks to his leadership, the business today is a global leader.”
 
GE Healthcare is the world’s leading manufacturer of medical imaging devices and also specializes in medical diagnostic tools and healthcare IT and software.
 
Flannery has been a key deal maker at GE this past year. He had a central role in GE’s recent purchase of France-based Alstom’s energy and transmission business as well as the spinoff of the company’s retail finance division, Synchrony Financial, which went public this year. He was also previously president and CEO of GE India and a senior leader at GE Capital.
 
By Laura Lorenzetti 
 
Source: Fortune

Related News

September 25, 2020

Novo Nordisk tees up phase 3 trial for once-weekly insulin

Life sciences

People with Type 2 diabetes are no strangers to needles, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others still doing […]

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]